Luteolin (peak 22) has been reported to inhibit the growth of gastric cancer cells (AGS), leading to detention at the G2/M phase by reducing the protein levels of Cdc2, Cyclin B1 and Cdc25 [56]. Here, CCNB1 is linked to gastric cancer.